What is the recommended treatment regimen for a patient with influenza pneumonia using oseltamivir (Tamiflu) and co-amoxiclav (Augmentin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Prescribe Tamiflu and Augmentin Together

For influenza pneumonia, immediately initiate oseltamivir (Tamiflu) 75 mg orally twice daily for 5 days plus co-amoxiclav (Augmentin) as first-line antibiotic therapy, with the specific antibiotic regimen stratified by pneumonia severity. 1, 2

Antiviral Therapy: Oseltamivir (Tamiflu)

Dosing and Duration:

  • Standard dose: 75 mg orally every 12 hours for 5 days 3, 1
  • Renal adjustment: Reduce to 75 mg once daily if creatinine clearance <30 mL/min 1, 3
  • Administration: May be taken with or without food, though tolerability is enhanced when taken with food 3, 4

Timing Considerations:

  • Ideally initiate within 48 hours of symptom onset 3, 5
  • However, hospitalized patients with pneumonia benefit from oseltamivir even when started >48 hours after symptom onset, particularly if immunocompromised 1, 2
  • Earlier initiation within 24 hours of admission significantly reduces 30-day mortality, especially in patients with respiratory failure 6

Antibiotic Therapy: Co-amoxiclav (Augmentin)

The antibiotic regimen depends entirely on pneumonia severity:

Non-Severe Influenza-Related Pneumonia (CURB-65 Score 0-2):

  • First-line oral therapy: Co-amoxiclav (amoxicillin-clavulanate) 7, 1, 2
  • Alternative: Doxycycline if co-amoxiclav is contraindicated 7, 1
  • Duration: 7 days for uncomplicated pneumonia 7, 1

Severe Influenza-Related Pneumonia (CURB-65 Score ≥3 or bilateral infiltrates):

  • Immediate IV combination therapy required: Co-amoxiclav OR 2nd/3rd generation cephalosporin (cefuroxime or cefotaxime) PLUS a macrolide (clarithromycin or erythromycin) 7, 1, 2
  • Critical timing: Antibiotics must be administered within 4 hours of admission 7, 1
  • Duration: 10 days for severe, microbiologically undefined pneumonia 7, 1

Route Switching Strategy:

  • Switch from IV to oral antibiotics when: Clinical improvement occurs AND temperature has been normal for 24 hours AND no contraindication to oral route exists 7, 2

Clinical Algorithm for Combined Therapy

Step 1: Confirm influenza pneumonia diagnosis

  • Use RT-PCR or nucleic acid amplification test for confirmation 8

Step 2: Assess pneumonia severity using CURB-65 score

  • Score ≥3 indicates severe pneumonia requiring hospitalization and IV therapy 9

Step 3: Initiate dual therapy immediately

  • Start oseltamivir 75 mg PO BID regardless of timing from symptom onset if hospitalized 1, 2
  • Start antibiotics within 4 hours: oral co-amoxiclav for non-severe OR IV combination therapy for severe 7, 1

Step 4: Monitor for treatment failure

  • For non-severe pneumonia not responding to co-amoxiclav: switch to fluoroquinolone with pneumococcal and staphylococcal coverage 7
  • For severe pneumonia not responding to combination therapy: add antibiotics effective against MRSA 7

Critical Pitfalls to Avoid

Common errors in prescribing this combination:

  • Do NOT withhold oseltamivir if >48 hours from symptom onset in hospitalized patients with pneumonia – they still benefit, especially if immunocompromised 1, 2
  • Do NOT use azithromycin monotherapy – it is inadequate for influenza-related pneumonia; co-amoxiclav is required as first-line 2
  • Do NOT delay antibiotics beyond 4 hours of admission – this critical window significantly impacts mortality 7, 1
  • Do NOT forget renal dose adjustment – oseltamivir requires reduction to 75 mg once daily if CrCl <30 mL/min 1, 3

Special Populations

High-risk patients requiring antibiotics even without confirmed pneumonia:

  • Patients with chronic comorbidities presenting with lower respiratory tract features should receive antibiotics in addition to oseltamivir 7
  • Previously well adults with worsening symptoms (recrudescent fever or increasing dyspnea) after initial improvement require antibiotic addition 7, 2

Immunocompromised patients:

  • Benefit significantly from oseltamivir even with delayed initiation 1, 2
  • May require extended prophylaxis up to 12 weeks in certain circumstances 3

Supportive Care Measures

  • Oxygen therapy: Maintain SpO2 >92% 1, 9
  • Antipyretics: Acetaminophen or ibuprofen for fever control; never aspirin in children <16 years due to Reye's syndrome risk 1, 2
  • Hydration: Maintain adequate oral or IV fluids 1, 9

References

Guideline

Treatment of Influenza Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Influenza-Like Illness

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[WHO clinical practice guidelines for influenza: an update].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), 2025

Guideline

Treatment of Streptococcal Infection and Influenza

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.